title: Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein.
abstract: Malaria merozoites require the presence of specific surface receptors on the red blood cell for invasion. Plasmodium vivax, requires the Duffy blood group antigen as an obligate receptor for invasion. The parasite Duffy binding protein (DBP) is the ligand involved in this process, making the DBP a potential vaccine candidate. A preliminary objective was to study whether people exposed to vivax malaria acquire antibodies that have the ability to block erythrocyte cytoadherence to the PvDBP. In comparison, we studied the immunogenicity of various recombinant DBP vaccines and investigated their potential to induct antifunctional antibodies. In order to do so, recombinant proteins to different regions of the putative ectodomain of the DBP and a DNA vaccine were used to immunize laboratory animals. An in vitro cytoadherence assay was used to investigate the presence of antifunctional antibodies in plasmas from people naturally exposed to vivax malaria, as well as in antisera obtained by animal vaccination. Our results showed that human plasma from populations naturally exposed to vivax malaria, as well as antisera obtained by vaccination using recombinant proteins, a DNA vaccine, and a synthetic peptide to DBP, inhibited in vitro binding of human erythrocytes to the DBP ligand domain (DBP(II)) in correlation to their previously measured antibody titer. Our results provide further evidence for the vaccine potential of this essential parasite adhesion molecule.
authors.affiliation: Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556-0369, USA.
authors.forename: P
authors.initials: P
authors.lastname: Michon
authors.forename: T
authors.initials: T
authors.lastname: Fraser
authors.forename: J H
authors.initials: JH
authors.lastname: Adams
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000494:pharmacology*; D000953:Antigens, Protozoan; D002352:Carrier Proteins / Q000276:immunology*; D002448:Cell Adhesion / Q000187:drug effects; D004375:Duffy Blood-Group System; D004912:Erythrocytes / Q000469:parasitology*; D006801:Humans; D017780:Malaria Vaccines / Q000276:immunology*; D016780:Malaria, Vivax / Q000276:immunology / Q000517:prevention & control; D010966:Plasmodium vivax / Q000276:immunology*; D015800:Protozoan Proteins; D011956:Receptors, Cell Surface / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D002352:Carrier Proteins; D004375:Duffy Blood-Group System; C066001:Duffy antigen binding protein, Plasmodium; D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011956:Receptors, Cell Surface; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic